Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer
Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer is a paper indexed in PICO Portal from OpenAlex.
How many citations does Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer have?
Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer has 544 citations in the OpenAlex counts PICO Portal stores.
When was Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer published?
Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer has 2020 year in the PICO Portal index.
What is the open-access status of Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer?
Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer has closed oa status in the PICO Portal index.
What is the DOI of Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer?
The DOI for Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer is on the source record.
What is the PMID of Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer?
The PMID for Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer is on the source record.
What is the OpenAlex record for Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer?
The OpenAlex for Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer is on the source record.